| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | HJ2; SER2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human JAG2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于JAG2抗体的3篇参考文献概览(注：文献为模拟示例，实际引用请根据具体论文调整)：
---
1. **标题**: "JAG2-mediated Notch signaling promotes tumor angiogenesis in colorectal cancer"
**作者**: Smith A, et al. (2021)
**摘要**: 研究利用JAG2特异性抗体，揭示了JAG2在结直肠癌血管生成中的作用。实验表明，抑制JAG2可通过阻断Notch信号通路减少肿瘤血管密度，为靶向治疗提供依据。
2. **标题**: "Development of a monoclonal antibody targeting JAG2 for therapeutic intervention in breast cancer"
**作者**: Chen L, et al. (2019)
**摘要**: 报道了一种新型抗JAG2单克隆抗体的开发，该抗体在乳腺癌模型中有效抑制肿瘤细胞增殖和转移，机制可能与下调Notch靶基因HES1相关。
3. **标题**: "JAG2 expression and antibody-based detection in triple-negative breast cancer subtypes"
**作者**: Gupta R, et al. (2020)
**摘要**: 通过免疫组化分析JAG2在三阴性乳腺癌中的表达，发现高表达JAG2与患者预后不良相关。研究验证了商用JAG2抗体的临床检测可靠性，提示其作为生物标志物的潜力。
---
如需具体文献，建议通过PubMed或Google Scholar搜索关键词“JAG2 antibody”或“JAG2 Notch therapeutic”获取最新研究。
The JAG2 antibody targets the Jagged2 (JAG2) protein, a key ligand in the Notch signaling pathway, which plays critical roles in cell-cell communication, differentiation, and tissue development. JAG2. a transmembrane protein belonging to the DSL (Delta/Serrate/LAG-2) family, binds to Notch receptors to activate downstream signaling. This pathway regulates diverse cellular processes, including stem cell maintenance, apoptosis, and immune responses. Dysregulation of JAG2-Notch signaling is implicated in cancers, developmental disorders, and immune diseases.
JAG2 antibodies are widely used in research to study protein expression, localization, and function. They enable detection of JAG2 in techniques like immunohistochemistry, flow cytometry, and Western blotting. In cancer biology, JAG2 overexpression has been observed in tumors such as breast, ovarian, and pancreatic cancers, correlating with poor prognosis and metastasis. Therapeutic JAG2-blocking antibodies are under exploration to inhibit oncogenic Notch activation.
Structurally, JAG2 contains extracellular EGF-like repeats, a DSL domain for receptor binding, and a cysteine-rich region. Antibodies may target specific domains to modulate signaling. Challenges include ensuring specificity due to homology with JAG1 and managing off-target effects. Current research also focuses on JAG2's role in immune regulation, particularly in T-cell development and autoimmune conditions. Both monoclonal and polyclonal JAG2 antibodies are available, each with distinct applications in basic and translational studies.
×
